On March 8, 2024, Intelligent Bio Solutions Inc., a Delaware-incorporated medical technology company, announced the entry into a Securities Purchase Agreement with several institutional and accredited investors. The agreement outlined the sale of 675,183 shares of common stock, Series I Pre-Funded Common Stock purchase warrants, and Series H-1 and H-2 warrants to purchase additional shares, in a private placement offering. The offering, which closed on March 12, 2024, was priced at $4.55 per share and warrant combination, resulting in gross proceeds of approximately $10.1 million before fees and expenses. The proceeds are intended for working capital and general corporate purposes. The company also entered into a Registration Rights Agreement, committing to file a resale registration statement with the SEC by March 18, 2024, and to have it declared effective by April 22, 2024. The securities were sold without registration under the Securities Act of 1933, in reliance on exemptions provided by Section 4(a)(2) and Rule 506 of Regulation D. Ladenburg Thalmann & Co. Inc. served as the placement agent for the offering, receiving cash fees, management fees, and warrants as compensation.

On March 8, 2024, Intelligent Bio Solutions Inc., a Delaware-incorporated medical technology company, announced the entry into a Securities Purchase Agreement with several institutional and accredited investors. The agreement outlined the sale of 675,183 shares of common stock, Series I Pre-Funded Common Stock purchase warrants, and Series H-1 and H-2 warrants to purchase additional shares, in a private placement offering. The offering, which closed on March 12, 2024, was priced at $4.55 per share and warrant combination, resulting in gross proceeds of approximately $10.1 million before fees and expenses. The proceeds are intended for working capital and general corporate purposes. The company also entered into a Registration Rights Agreement, committing to file a resale registration statement with the SEC by March 18, 2024, and to have it declared effective by April 22, 2024. The securities were sold without registration under the Securities Act of 1933, in reliance on exemptions provided by Section 4(a)(2) and Rule 506 of Regulation D. Ladenburg Thalmann & Co. Inc. served as the placement agent for the offering, receiving cash fees, management fees, and warrants as compensation.